Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Collaboration › Details

Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform

 

Period Period 2020-01-07
Organisations Partner, 1st Boehringer Ingelheim (Group)
  Partner, 2nd PhoreMost Ltd.
Products Product drug target identification
  Product 2 Siteseeker® drug target discovery technology
     

PhoreMost Ltd.. (1/7/20). "Press Release: PhoreMost and Boehringer Ingelheim Enter Multi-project Drug Discovery Collaboration". Cambridge.

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim’s discovery programmes


PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments. Under the terms of the agreement, PhoreMost will receive an upfront payment and research funding together with downstream success-based milestones. Further financial terms are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, towards disease relevant pathways nominated by Boehringer Ingelheim. Novel targets identified will be further validated and characterised by Boehringer Ingelheim as part of its internal Discovery Research pipeline. Boehringer Ingelheim’s Research programme is active in the fields of immunology and respiratory diseases, cardiometabolic diseases, oncology research and immuno-oncology, as well as diseases of the central nervous system.

The SITESEEKER platform is based on PhoreMost’s core proprietary protein interference, or ‘PROTEINi’, technology. Using SITESEEKER, PhoreMost probes the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease, using the vast 3-D shape diversity of natural protein fragment (sub-domain) libraries. This enables the systematic unmasking of cryptic druggable sites, directly linking them to useful therapeutic functions.

Dr Chris Torrance, CEO of PhoreMost, said: “We are delighted that Boehringer Ingelheim has chosen to work with PhoreMost to enhance its drug discovery pipeline with attractive biological starting points. The collaboration is further recognition of the ability of PROTEINi and SITESEEKER to identify novel targets, and we look forward to working with the Boehringer Ingelheim team on these projects.”


ENDS

Notes to Editors:

Contacts

Media enquiries
Katie Odgaard
Zyme Communications
E-mail: katie.odgaard@zymecommunications.com
Phone: +44 (0)7787 502 947

PhoreMost Ltd
Dr Neil Torbett, CBO
E-mail: neil.torbett@phoremost.com


To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.


About PhoreMost Ltd
www.phoremost.com

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.

   
Record changed: 2020-01-07

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Boehringer Ingelheim (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px




» top